D3 bio is a global biotechnology company focusing on the development of cancer and immune precision therapy drugs
Location: China
Employees: 11-50
Total raised: $348M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 09.02.2022 | Matrix Par... | matrixpart... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.12.2025 | Series B | $108M | Temasek Ho... |
| 08.04.2024 | - | $40M | - |
| 18.11.2020 | Series A | $200M | - |
Mentions in press and media 19
| Date | Title | Description |
| 01.06.2026 | D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC | Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81.3% in first-line K... |
| 30.04.2026 | D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types | Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D, 600 mg QD). Phase 2 clinical outcomes include: 2L+ KRAS G12Ci–naïve NSCLC: ORR of 58.8%, mPFS of 12.2 months 2L+ colorecta... |
| 20.03.2026 | D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session | SHANGHAI, March 20, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is pleased to announce that five abstracts have been accepted for presentation at... |
| 19.01.2026 | D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002 | SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Inves... |
| 15.12.2025 | D3 Bio Secures $108M to Advance Cancer Drug Trials Globally | D3 Bio, a Shanghai-based biotech, just raised $108 million. This Series B funding fuels late-stage trials. The focus? Elisrasib, a drug targeting KRAS G12C-mutant cancers. Trials will span the US, China, and Europe. The company aims for glo... |
| 14.12.2025 | D3 Bio: $108 Million Series B Raised To Fund Global Phase III Trials For Lead KRAS G12C Program | D3 Bio has raised $108 million in a Series B financing round to support late-stage clinical development of its lead oncology candidate and advance a broader pipeline of targeted and immuno-oncology programs. The Shanghai-based clinical-stag... |
| 12.12.2025 | Temasek-backed D3 Bio secures $108 M Series B funding to advance global clinical programs | A $108 million Series B financing round has been completed, according to D3 Bio, a global clinical-stage biotechnology company dedicated to the discovery and development of novel oncology therapeutics. A notable group of investors, includin... |
| 11.12.2025 | Temasek, HongShan-backed D3 Bio raises $108m in Series B round | - |
| 10.12.2025 | Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans | A Chinese biotech helmed by an AstraZeneca veteran has secured $108 million in series B funds, which the company will use to advance its lead KRAS inhibitor into phase 3 studies. D3 Bio saw previous investors like WuXi AppTec's Corporate Ve... |
| 10.12.2025 | D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs | SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round.... |
Show more